Non-transferrin-bound iron in plasma following administration of oral iron drugs - PubMed (original) (raw)
Clinical Trial
Non-transferrin-bound iron in plasma following administration of oral iron drugs
Bernd Dresow et al. Biometals. 2008 Jun.
Abstract
Non-transferrin-bound iron (NTBI) was detected in serum samples from volunteers with normal iron stores or from patients with iron deficiency anaemia after oral application of pharmaceutical iron preparations. Following a 100 mg ferrous iron dosage, NTBI values up to 9 muM were found within the time period of 1-4 h after administration whereas transferrin saturation was clearly below 100%. Smaller iron dosages (10 and 30 mg) gave lower but still measurable NTBI values. The physiological relevance of this finding for patients under iron medication has to be elucidated.
Similar articles
- Changes in non-transferrin-bound iron (NTBI) in pregnant women on iron supplements.
Baron J, Ben-David G, Hallak M. Baron J, et al. Eur J Obstet Gynecol Reprod Biol. 2008 Oct;140(2):281-2. doi: 10.1016/j.ejogrb.2008.01.002. Epub 2008 Mar 4. Eur J Obstet Gynecol Reprod Biol. 2008. PMID: 18304722 Clinical Trial. No abstract available. - Common presence of non-transferrin-bound iron among patients with type 2 diabetes.
Lee DH, Liu DY, Jacobs DR Jr, Shin HR, Song K, Lee IK, Kim B, Hider RC. Lee DH, et al. Diabetes Care. 2006 May;29(5):1090-5. doi: 10.2337/diacare.2951090. Diabetes Care. 2006. PMID: 16644642 - [Diagnostics and treatment of iron-deficiency anemia].
Rajamäki A, Punnonen K. Rajamäki A, et al. Duodecim. 1998;114(12):1187-93. Duodecim. 1998. PMID: 11524764 Review. Finnish. No abstract available. - Impact of oral iron challenges on circulating non-transferrin-bound iron in healthy Guatemalan males.
Schümann K, Kroll S, Romero-Abal ME, Georgiou NA, Marx JJ, Weiss G, Solomons NW. Schümann K, et al. Ann Nutr Metab. 2012;60(2):98-107. doi: 10.1159/000336177. Epub 2012 Mar 6. Ann Nutr Metab. 2012. PMID: 22398912 Clinical Trial. - Prepartum anaemia: prevention and treatment.
Milman N. Milman N. Ann Hematol. 2008 Dec;87(12):949-59. doi: 10.1007/s00277-008-0518-4. Epub 2008 Jul 19. Ann Hematol. 2008. PMID: 18641987 Review.
Cited by
- Role of redox iron towards an increase in mortality among patients: a systemic review and meta-analysis.
Sharma S. Sharma S. Blood Res. 2019 Jun;54(2):87-101. doi: 10.5045/br.2019.54.2.87. Epub 2019 Jun 25. Blood Res. 2019. PMID: 31309086 Free PMC article. Review. - Can Iron Treatments Aggravate Epistaxis in Some Patients With Hereditary Hemorrhagic Telangiectasia?
Shovlin CL, Gilson C, Busbridge M, Patel D, Shi C, Dina R, Abdulla FN, Awan I. Shovlin CL, et al. Laryngoscope. 2016 Nov;126(11):2468-2474. doi: 10.1002/lary.25959. Epub 2016 Apr 23. Laryngoscope. 2016. PMID: 27107394 Free PMC article. Clinical Trial. - Safety and efficacy of sucrosomial iron in inflammatory bowel disease patients with iron deficiency anemia.
Abbati G, Incerti F, Boarini C, Pileri F, Bocchi D, Ventura P, Buzzetti E, Pietrangelo A. Abbati G, et al. Intern Emerg Med. 2019 Apr;14(3):423-431. doi: 10.1007/s11739-018-1993-9. Epub 2018 Nov 29. Intern Emerg Med. 2019. PMID: 30499070 - The pharmacokinetics and pharmacodynamics of iron preparations.
Geisser P, Burckhardt S. Geisser P, et al. Pharmaceutics. 2011 Jan 4;3(1):12-33. doi: 10.3390/pharmaceutics3010012. Pharmaceutics. 2011. PMID: 24310424 Free PMC article. - Mechanism of Action and Clinical Attributes of Auryxia® (Ferric Citrate).
Ganz T, Bino A, Salusky IB. Ganz T, et al. Drugs. 2019 Jun;79(9):957-968. doi: 10.1007/s40265-019-01125-w. Drugs. 2019. PMID: 31134521 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical